In lab experiments, the research team used cell lines derived from 40
patient tumour samples to identify that CD151 contributes to the survival of cells of high - grade serous ovarian cancer origin.
Prostate cancer researchers have mapped the impact of an acquired mutation that alters epigenetic identity, the make - up of DNA, in about 50 % of
patient tumour samples.
Not exact matches
Scientists at The Institute of Cancer Research, London, analysed 177
tumour samples from
patients with stage I non-seminomatous
tumours enrolled in clinical trials through the Medical Research Council (MRC) Clinical Trials Unit.
With
tumour diagnosis, for example, surgeons usually remove a
sample for analysis while the
patient waits on the operating table.
It will soon be time to take
samples of the 3 cm invisible
tumour hidden in the
patient's left lung.
«We therefore looked for
patient characteristics that would account for this result; next generation sequencing (NGS) of the genes of interest was performed on the archival tissue
samples from the
patients» primary
tumours,» explained Ciardiello.
In a study of 40
patients with high grade serous ovarian cancer, the researchers monitored
tumour DNA that could be detected in a blood
sample taken before each chemotherapy treatment.
The research team with international collaborators analysed more than 100
patient samples from ovarian and other cancer types to discover a distinct population of cells found in some
tumours.
Samples of
tumours from bowel cancer
patients given different doses of resveratrol showed that even lower doses can get into cancer cells and potentially affect processes involved in
tumour growth.
To do this, they switched from using dead
tumour cell
samples to
patient - derived
tumour cell lines, in which fresh
samples of a person's
tumour are grafted onto mice and grown to the required volumes.
The authors of the work also show that NANOG is increased in
patient - derived
tumour samples from stratified epithelia.
In collaboration with Dr Gabriele Bonatz from the Augusta clinics in Bochum (Brustzentrum), Hatt's team confirmed the existence of TRPV1 in
tumour cells in nine different
samples from
patients suffering from breast cancer.
Carried out in cells in the laboratory, in mice and in
samples from
patients»
tumours, the researchers showed this «safe haven» lets melanoma cells turn on a parallel set of cell signals that helps them survive.
Using
samples from 280 breast cancer
patients, the researchers found that tamoxifen had a weak or limited effect on
tumours with a highly active BCAR4 gene.
By conducting an RNA - sequencing experiment of 103 matched
tumour and normal colon mucosa
samples from Danish CRC
patients, 90 of which were germline - genotyped, researchers from the collaborative European project SYSCOL show that both inherited and acquired mutations in non-coding regions of the genome also contribute to cancer development and progression (Linda Koch, Nature Reviews Genetics).
In the new study, scientists at King's College London, led by Dr Anita Grigoriadis from the Breast Cancer Now Research Unit at King's College London, studied lymph node tissue and primary
tumour samples from 309 breast cancer
patients, who were treated between 1984 and 2002 at Guy's Hospital London.
Several studies have demonstrated the feasibility of molecular screening of
tumour samples for matching
patients with cancer to targeted therapies.